Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: University of South Carolina
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Anemia, Sickle Cell|Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05261711 |
(SCD) | P2 |
Terminated |
Anemia, Sickle Cell |
2024-10-01 |
2024-12-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01204957 |
USCIRB#060701 | P2 |
Completed |
Breast Cancer |
1999-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|